Director/PDMR Shareholding

Venture Life Group PLC

("Venture Life" or the "Company")

Director/PDMR Shareholdings

Bracknell, UK - 9 May 2016: Venture Life Group plc (AIM: VLG), the international consumer healthcare group addressing the self-care needs of the ageing population, announces that it was informed on 6 May 2016 that Mr. Jerry Randall, the Chief Executive Officer of the Company, has transferred 20,000 ordinary shares of 0.3p each in the Company ("Ordinary Shares") to his SIPP (the "Transfer"). The Transfer was made on 6 May 2016 by way of a sale at a price of 53.00p per Ordinary Share and purchase at a price of 53.10p per Ordinary Share. Following the Transfer, Mr. Randall's beneficial interest in the Company remains unchanged at 3,931,129 Ordinary Shares, representing approximately 10.7% of the issued share capital in the Company.

The Company was separately informed on 6 May 2016 that Mr. James Hunter, the Chief Financial Officer of the Company, has transferred 36,697 Ordinary Shares to his SIPP (the "Transfer"). The Transfer was made on 6 May 2016 by way of a sale at a price of 53.00p per Ordinary Share and purchase at a price of 53.08p per Ordinary Share. Following the Transfer, Mr. Hunter's beneficial interest in the Company remains unchanged at 43,840 Ordinary Shares, representing approximately 0.1% of the issued share capital in the Company.

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer +44 (0)1344 742 870

James Hunter, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Broker) Freddy Crossley +44 (0) 20 7886 2500

Peter Steel

Duncan Monteith Corporate Finance

Tom SalvesenCorporate Broking

Square1 Consulting

David Bick

Brian Alexander +44 (0)20 7929 5599

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.